RemeGen Co (SHSE:688331) EPS (Basic) : ¥-2.95 (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is RemeGen Co EPS (Basic)?

RemeGen Co's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was ¥-1.45. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-2.95.

RemeGen Co's EPS (Diluted) for the six months ended in Jun. 2024 was ¥-1.45. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-2.95.

RemeGen Co's EPS without NRI for the six months ended in Jun. 2024 was ¥-1.44. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -2.94.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

RemeGen Co EPS (Basic) Historical Data

The historical data trend for RemeGen Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co EPS (Basic) Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.90

-1.71

0.57

-1.88

-2.80

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial							-0.96	-0.92	-1.30	-1.50	-1.45

RemeGen Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

RemeGen Co's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1511.229	-	0)	/	538.914
	=	-2.80

RemeGen Co's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-780.46	-	0)	/	537.632
	=	-1.45

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ¥-2.95

RemeGen Co (SHSE:688331) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

RemeGen Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of RemeGen Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

No Headlines